New techniques in plant biotechnology old deficiencies in risk assessment



Dr. Eva Gelinsky – GMO-Free Europe – 7th May 2015

The Federal Ethics Committee on Non-Human Biotechnology (ECNH)

Our mandate includes:

•to observe and evaluate the developments and applications of nonhuman biotechnology from an ethical point of view

•to advice the Federal Council and the Federal Administration on ethical issues in the preparation of legislation

•to advice the authorities on the enforcement of federal regulations

•to provide information and advance public debate on the risks of biotechnology



Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Federal Administration admin.ch

Federal Ethics Committee on Non-Human Biotechnology ECNH

The Federal Ethics Committee on Non-Human Biotechnology (ECNH)

A typical procedure:

1. Arising of a new technology and arising awareness of new ethical issues coming up

 \rightarrow sources of information: scientific publications and media, other federal expert committees and federal administration

2.Phase of collecting information: What exactly is at stake? → expert hearings, research, what arguments are brought forward by stakeholders?

3.Creating an "ethical landscape": What are the objectives of the technology resp. its application? What ethical values are at stake? What are the risks/consequences of the technology?

ightarrow internal and external ethical expert opinions, debate

4. Writing an advisory opinion

 \rightarrow Publication, Press Conference





New Plant Breeding Techniques and Risks Associated with their Application by Michael Eckerstorfer, Marianne Miklau, Helmut Gaugitsch, Environment Agency Austria, Vienna, commissioned by ECNH, March 2014


http://www.ekah.admin.ch

- → New techniques in Plant Biotechnology: too technical, too complicated?
- → Are the new GM plants **safe** or are they **risky**?
- \rightarrow Old deficiencies in risk assessment: Just read the statements of the proponents thoroughly.

"There is no evidence that GM technologies are any riskier than conventional breeding technologies and this has been confirmed by thousands of research projects."

Anne Glover, Interview on 'Planting the future', report of the European Academies of Science Advisory Council (EASAC) at http://www.euractiv.com

"Using these [new] techniques, potential adverse effects are even less likely than in conventional transgenic plants or plants resulting from conventional breeding. The combination of various new techniques will allow precise genetic modification, resulting in plants that harbour as little recombinant DNA as possible or none at all."



Hartung, F., Schiemann, J. 2014: Precise plant breeding using new genome editing techniques: opportunities, safety and regulation in the EU. In: The Plant Journal (2014) 78, 750

In view of the "promising novel plant breeding technologies, post- GM, (...) we shouldn't make the mistake of regulating them to death as we have done with GM."



Anne Glover, Interview on 'Planting the future', report of the European Academies of Science Advisory Council (EASAC) at http://www.euractiv.com

No regulation?

"[T]here is no scientific reason to classify a plant as a transgenic organism, (...) if there is no foreign recombinant DNA in its genome."


"NPBTs or other future techniques, should be evaluated according to the new trait and the resulting end product rather than the technique used to create the new plant variety."



Hartung, F., Schiemann, J. 2014: Precise plant breeding using new genome editing techniques: opportunities, safety and regulation in the EU. In: The Plant Journal (2014) 78, 742/750

Beware of Europe's competitiveness

If the new techniques fall under the scope of GM legislation in Europe "there is the risk that scientists and companies will move elsewhere, accelerating the negative impact on the science base and on Europe's competitiveness."



Heap, B. (2013) Europe should rethink its stance on GM crops. Nature, 498, 409, cited by Hartung, F., Schiemann, J. 2014: Precise plant breeding using new genome editing techniques: opportunities, safety and regulation in the EU. In: The Plant Journal (2014) 78, 750

Old arguments...

- 1. It is asserted that GM plants are safe.
- 2. New GM plants are even safer, because the techniques are more precise.
- Change the whole GM regulation to a product-based assessment (versus process-based) and/or:
- 4. Don't regulate at all.
- Why? Because there's scientific evidence and we have to be aware of future competitiveness of the European plant breeding sector.



First explanatory model

GMP = Plant of origin + additional properties inserted by gene technology

Essentially based on concept of Substantial Equivalence

 Biochemical and toxicological properties in comparison to the original product substantially unaltered.



• Inserted properties are neither toxic nor allergenic.

Concept used to assess food safety with regard to human health Influences the evaluation of the impact of GM plants onto the environment

Second explanatory model

GMP is *more* than plant of origin and additional properties inserted by gene technology

→ possible unexpected effects



Evaluation restricted to certain effects of the transgene considered insufficient

Typical risk situation:

Evaluation of GM plants = risk evaluation

Recommendations

1. Apply the risk model

New GM: Assess the *process* and the *product*


- 2. Apply the precautionary principle
- 3. Step-by-step approach
- 4. Independent risk research New GM: Urgent, no data!
- 5. Monitoring
- 6. Freedom of choice and protection of GM-free (seed) production

New GM: Don't create precedents

New GM: Genetic engineering in the process and/or in the product: regulate as GMOs

If not/not clear: moratorium (my suggestion)

Thank you!



Dr. Eva Gelinsky - GMO-Free Europe - 7th May 2015